Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05699174 · ClinicalTrials.gov registry record · Phase 3

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

A Phase 3 study of Amputation and Infections, sponsored by Major Extremity Trauma Research Consortium.

Recruiting
Registry status
Phase 3
Development phase
250
Enrollment target
13
Study locations

NCT05699174 is a Phase 3 study of Amputation and Infections that is actively recruiting participants, run by Major Extremity Trauma Research Consortium. The registered enrollment target is 250 participants, above the 129-participant average among 65 other Amputation trials with a reported enrollment target (94% higher). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05699174, a Phase 3 study of Amputation and Infections, is actively recruiting participants, sponsored by Major Extremity Trauma Research Consortium.

RECRUITING
Registry status
Phase 3
Development phase
250 participants
Enrollment target
13
Study locations

Study Summary

This is a Phase III clinical randomized control trial to investigate differences between patient with an infected nonunion treated by PO vs. IV antibiotics. The study population will be 250 patients, 18 years or older, being treated for infected nonunion after internal fixation of a fracture with a segmental defect less than one centimeter. Patients will be randomly assigned to either the treatment (group 1) PO antibiotics for 6 weeks or the control group (group 2) IV antibiotics for 6 weeks. The primary hypothesis is that the effectiveness of oral antibiotic therapy is equivalent to traditional intravenous antibiotic therapy for the treatment of infected nonunion after fracture internal fixation, when such therapy is combined with appropriate surgical management. Clinical effectiveness will be measured as the primary outcome as the number of secondary re-admissions related to injury and secondary outcomes of treatment failure (re-infection, nonunion, antibiotic complications) within the first one year of follow-up, as defined by specified criteria and determined by a blinded data assessment panel. In addition, treatment compliance, the cost of treatment, the number of surgeries required, the type and incidence of complications, and the duration of hospitalization will be measured.

Interventions

  • DRUG Standard of Care PO (oral) antibiotics
  • DRUG Standard of Care Intravenous (IV) antibiotics

Study Locations (13)

Maryland

  • University of Maryland , MD Department of Orthopaedics - Baltimore
  • Sinai Hospital Baltimore - Baltimore

North Carolina

  • Atrium Health, Carolinas Medical Center - Charlotte
  • Wake Forest University Baptist Medical Center - Winston-Salem

Indiana

  • Indiana University - Indianapolis

Minnesota

  • Hennepin Health - Minneapolis

New York

  • Jamaica Hospital Medical Center - Queens

Oklahoma

  • University of Okalahoma College of Medicine - Oklahoma City

Pennsylvania

  • Penn State University M.S. Hershey Medical Center - Hershey

Tennessee

  • Vanderbilt Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2023-05-30
Est. Completion 2027-09-29
Phase Phase 3

What the Registry Record Tells You About NCT05699174

The ClinicalTrials.gov registry entry for NCT05699174 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 129-participant average among 65 other Amputation trials with a reported enrollment target (94% higher). The listed sponsor is Major Extremity Trauma Research Consortium, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Amputation appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care PO (oral) antibiotics is the first listed.

NCT05699174 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Maryland, North Carolina, Indiana.

Frequently Asked Questions

What is clinical trial NCT05699174 about?

NCT05699174 is a clinical study titled "PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation". This is a Phase III clinical randomized control trial to investigate differences between patient with an infected nonunion treated by PO vs. IV antibiotics. The study population will be 250 patients, 18 years or older, being treated for infected nonunion after internal fixation of a fracture with a ...

What is the current status of trial NCT05699174?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2023-05-30. Estimated completion is 2027-09-29.

What conditions does trial NCT05699174 study?

This clinical trial studies the following conditions: Amputation, Infections, Fracture, Lower Extremity Fracture, Nonunion of Fracture.

What interventions are being tested in trial NCT05699174?

The interventions under investigation include: Standard of Care PO (oral) antibiotics (DRUG), Standard of Care Intravenous (IV) antibiotics (DRUG).

Who is sponsoring clinical trial NCT05699174?

This trial is sponsored by Major Extremity Trauma Research Consortium, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05699174 being conducted?

This trial has 13 study locations across Indiana, Maryland, Minnesota, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amputation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.